Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

Nastech's PTH Nasal Spray Lands $577M P&G Deal

Feb. 2, 2006

Shares of Nastech Pharmaceutical Co. Inc. jumped 18 percent Wednesday on news of a potential $577 million deal with Procter & Gamble Pharmaceuticals Inc. to develop Nastech's nasal spray for osteoporosis. (BioWorld Today)

Gilead Beats Consensus; Truvada Sales Fall Short

Feb. 1, 2006

By Jennifer Boggs

Gilead Beats Consensus; Truvada Sales Fall Short

Feb. 1, 2006

By Jennifer Boggs

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Jan. 27, 2006

By Jennifer Boggs

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Jan. 27, 2006

By Jennifer Boggs

Targeted Genetics Trims Staff, Cash Burn To Focus On Clinic

Jan. 26, 2006

By Jennifer Boggs

Targeted Genetics Trims Staff, Cash Burn To Focus On Clinic

Jan. 26, 2006

By Jennifer Boggs

VC Financing Steady In 2005; Investors Favoring Late Stage

Jan. 25, 2006

By Jennifer Boggs

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Jan. 25, 2006

By Jennifer Boggs

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Jan. 25, 2006

By Jennifer Boggs

View All Articles by Jennifer Boggs

Jennifer Boggs

ARTICLES

Nastech's PTH Nasal Spray Lands $577M P&G Deal

Gilead Beats Consensus; Truvada Sales Fall Short

Gilead Beats Consensus; Truvada Sales Fall Short

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Targeted Genetics Trims Staff, Cash Burn To Focus On Clinic

Targeted Genetics Trims Staff, Cash Burn To Focus On Clinic

VC Financing Steady In 2005; Investors Favoring Late Stage

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Today's news in brief

Today's news in brief

News in brief

Biopharma tariffs becoming more than a threat

New Trump order zeroes in on drug prices